젊은 연령층과 고령층에서 발생하는 뇌동맥류의 임상적 비교연구

전용선,송시헌,고현송,염진영,김성호,김윤 대한신경외과학회 1998 Journal of Korean neurosurgical society Vol.27 No.8

生體血의 保存環境과 腐敗産物에 依한 血中알콜濃度變化에 關한 硏究

張成吉,金英雲,柳在薰,吳世珍,權五星,朴世延 內務部 國立科學搜査硏究所 2001 國立 科學 搜査 硏究所 年報 Vol.33 No.-

Space Supervision을 이용한 치성 정중선 변위의 교정

김수연,최영철,박재홍,최성철,김광철 大韓小兒齒科學會 2007 大韓小兒齒科學會誌 Vol.34 No.4

상하악 중절치 간의 정중선 변위는 골격성 변위,치성 변위 및 골격성과 치성의 복합적 변위 등으로 구분된다. 그 중 치성 정중선 변위는 치열의 발육시기에 따라 다양한 방법으로 치료 방법을 선택할 수 있다. 특히 혼합치열의 초기에는 치열 내에 존재하는 공간의 조건,인접 영구치의 맹출 시기 또는 맹출 방향에 따라 영구 절치들의 위치가 자발적으로 변화,개선될 수 있다. 따라서 이러한 치아의 생리적 이동을 이용하여 특별한 교정장치의 이용 없이 치열 내에서 치아의 배열을 개선시킬 수 있다. 본 증례보고에서는 특히 유견치의 발거 시기 및 좌우 유치의 발거 순서 등을 이용하여 치성 정중선 불일치를 개선시킨 증례틀을 보고하고자 한다. A midline deviation is divided into three types, such as a skeletal midline deviation, a dental midline deviation, and a combination. Among them, the midline deviation which appear in the early mixed dentition without any skeletal problem can be managed differently by the stage of dental development. The location of the permanent incisors can be improved without using artificial force in consideration of the condition of the space, the eruption timing or the eruption path of the adjacent permanent teeth in early mixed dentition, especially when the permanent incisors are erupting. Therefore. the space supervision technique, which can have the teeth align themselves utilizing physiologic events such as sequence or timing of the eruption of permanent teeth, can be an alternative to orthodontic movement. This case report describes midline deviation improvement by space supervision.

자동화학검사용 인화시약의 평가

이성규,공선영,송선미,이수연,김종원 대한임상검사정도관리협회 1992 臨床檢査와 精度管理 Vol.22 No.2

일부 청소년들에서 흡연노출량에 따른 혈중 카드뮴 농도

장성실,권윤형,배진순,노영만,한진구 韓國學校保健學會 2001 韓國學校保健學會誌 Vol.14 No.2

Objectives: We surveyed the prevalence of smoking among the adolescent population and analysed the correlation of the two exposure biomarkers-concentration of blood cadmium and urinary cotinine-to the smoking status. Methods: Subjects were 193 middle and high school students in Chungnam province. Blood cadmium and urinary cotinine were compared by sex and smoking status. Smoking status were classified by either the concentration of urinary cotinine or subjective answering as a smoker in the questionnaire. Results: Smoking prevalence was 24.6%, 36.2% and 6.7% among all subjects, male and female subjects, respectively. Average smoking amount was 17.5 and 1.5 cigarettes per month among the male subjects and female subjects, respectively Mean concentration of urinary cotinine among the male subjects was 135.57 ㎍/ℓ, and that of female subjects was 116.59 ㎍/. Direct smokers showed higher concentration of urinary cotinine than those of indirect smokers, and subjects with higher urinary concentration showed higher prevalence of smoking, too. Mean concentration of blood cadmium was 0.0572 ㎍/㎗ among the male subjects, and 0.0693 ㎍/㎗ among the female subjects. Among the male subjects, both exposure biumarkers showed significant correlation to the smoking status, but among the female subjects urinary cotinine did not show significant correlation to the smoking status. Conclusion: Concentrations of these two biomarkers suggested that this population had significantly high evironmental tobacco smoking(ETS) and efficient stop-smoking programs to reduce ETS should be directed to this population. Key words : environmental tobacco smoking, urinary cotinine, blood cadmium

保存血의 腐敗産物에 依한 에틸알콜 生成濃度에 關한 硏究(Ⅱ)

張成吉,金英雲,柳在薰,權五星,朴世延 內務部 國立科學搜査硏究所 2002 國立 科學 搜査 硏究所 年報 Vol.34 No.-

자동화학검사용 영동시약의 평가

이성규,공선영,송선미,이수연,김종원 대한임상검사정도관리협회 1992 臨床檢査와 精度管理 Vol.22 No.2

2.9% 과산화수소를 함유한 부착형 미백제의 임상적 효능과 안정성에 관한 연구

박은숙,성소래,홍성태,김지은,이소영,황수연,이신재,진보형,손호현,조병훈 大韓齒科保存學會 2006 Restorative Dentistry & Endodontics Vol.31 No.4

2.9%의 과산화수소를 함유한 시험용 부착형 미백제(Medison dental whitening strip, Samsung medical Co.,Anyang,Korea)를 실험군 피험자 23명, 시험용 미백제에서 과산화수소를 제외한 동일한 제재를 대조약으로 대조군 피험자 24명에게 매일 1시간 30분씩, 2주간 적용하여 임상적 효능과 안전성을 평가하였다. 미백 효과는 Shade Vision, Chroma Mete 및 Vitapan classical shade guide를 이용하여 색변화를 측정하여 다음과 같은 결론을 얻었다. 1. 실험군에서의 전체 치아의 색변화량(ΔE^(*))은 세 가지 측정법에서 모두 대조군에 비해 통계적으로 유의한 차이를 보였고 (p < 0.05). 쉽게 인지할 수 있는 정도였다. 2. 색변화는 색좌표 상에서 명도의 증가와 녹색조 및 청색조로의 변화에 의해 얻어졌다. 3. 치아별로는 어두운 견치의 색변화량이 가장 컸고, 측절치, 중절치 순으로 감소하였다. 4. 47명의 피험자 중 5명이 경도의 과민증을 경험하였으나 곧 완화되었다, 치은염증지수와 전기치수검사 결과 시험 전후에 차이가 없어 안전성을 확인하였다. This study evaluated the effectiveness and safety of an experimental bleaching strip (Medison dental whitening strip, Samsung medical Co., Anyang, Korea) containing 2.9% hydrogen peroxide. Twenty-three volunteers used the bleaching strips for one and a half hour daily for 2 weeks. As control group, the same strips in which hydrogen peroxide was not included were used by 24 volunteers with the same protocol. The shade chang (ΔE^(*), color differnce) of twelve anterior teeth was measured using Shade Vision (X-Rite Inc., S. W. Grandville, MI, USA), Chroma Meter (Minota Co., Ltd. Osaka, Japan) and Vitapan classical shade guide (Vita Zahnfabrik, Germany). The shade change of overall teeth in the experimental group was significantly greater than that in the control group (p < 0.05) and was easily perceivable. The change resulted from the increase of lightness (CIE L^(*) value) and the decrease of redness (CIE a^(*) value) and yellowness (CIE b^(*) value). The shade change of individual tooth was greatest in canine, can smallest in central incisor. The safety of the bleaching strip was also confirmed. 〔J Kor Acad Cons Dent 31(4):269-281, 2006〕

고콜레스테롤 혈증 환자에서 Cerivastatin(LIPOBAY, 의과학연구소)의 임상효과 및 안전성에 관한 연구

박성훈,김미연,정수진,이영숙,박창한,변은경,전성희 梨花女子大學校 醫科大學 醫科學硏究所 2001 EMJ (Ewha medical journal) Vol.24 No.3

목적 : Cerivastatin(LIPOBAY)은 최근에 개발되어 사용되기 시작한 HMG-CoA 환원효소 억제제로서 저용량으로 탁월한 콜레스테롤 강하효과를 보이는 약물이다. 저자들은 Cerivatatin(LIPOBAY)의 혈중 콜레스테롤 강하효과를 평가하고 약물의 안전성을 평가하기 위하여 본 연구를 시행하였다. 방법 : 고콜레스테롤혈증 환자 37명(남자 13명, 여자 24명)을 대상으로 하였다. 대상환자는 2주간의 저콜레스테롤 식이 후에도 혈청 콜레스테롤이 240㎎/㎗이상이거나, 관상동맥질환이 있는 환자는 혈청콜레스테롤이 220㎎/㎗이상인 경우 cerivastatin 0.4㎎을 8주간 복용하도록 하였다. 임상적 관찰과 검사실 검사(간기능검사, 일반혈액검사, 혈청지질검사)는 투약개시 후 4주 및 8주 후에 시행하였다. 결과 : Cerivastatin 0.4㎎을 4주간 투여한 후 측정한 LDL 콜레스테롤, 총콜레스테롤, triglyceride, 및 HDL 콜레스테롤은 각각 38%, 28.8%, 11.6% 및 7.8% 감소하였다. 총콜레스테롤/HDL 콜레스테롤 비 및 LDL/HDL비는 각각 20.8% 및 31.1% 감소하였다. 투약 8주후에 측정한 검사소견은 4주후에 비해 유의한 변화를 보이지 않았다. 한명의 환자(2.7%)에서 간기능 검사상 AST, 및 ALT의 지속적인 상승으로 투약을 중지하였다. 결론 : Cerivastatin 0.4㎎/day는 혈청콜레스테롤을 효과적으로 감소시켰으며 심각한 부작용은 볼 수 없었다. 따라서 적극적으로 LDL콜레스테롤을 낮출 필요가 있는 고콜레스테롤혈증 환자에서 cerivastatin은 효과적이고 안전한 약물이라고 생각된다. Objectives : Cerivastain(LIPOBAY) is recently developed HMG-CoA reductase inhibitor which is effective in lowering serum cholesterol levels at microgram does. We evaluated the clinical efficacy and safety of cerivastatin(LIPOBAY) in patients with hypercholesterolemia. Method : Thirty-seven patients(male : 13, female : 24) with hypercholesteolemia defined as baseline serum total cholesterol ≥240㎎/㎗, or ≥220㎎/㎗ in patients with known coronary artery disease were included for this study. After 2 weeks of low cholesterol diet, if the serum total choesterol level meet the criteria, cerivastain 0.4㎎/day was prescribed for 8 weeks. Clinical follow-up and laboratory tests were performed 4 weeks and 8 weeks after medication. Results : After 4 weeks of cerivastain 0.4㎎/day treatment, low density lipoprotein(LDL) cholesterol decreased 38% and total cholesterol decreased 28.8% from baseline. Triglyceride decreased 11.6%, and high density lipoprotein(HDL) cholesterol decreased 7.8% from baseline. Total cholesterol/HDL ratio decreased 20.8% and LDL/HDL ratio decreased 31.1% from baseline. After 8 weeks of treatment, no further significant changes were noted compared with the values at 4 weeks. Cervastatin was discontinued in one patient(2.7%) due to continuous liver enzyme elevation. Conclusion : Cerivastatin 0.4㎎/day is effective in lowering serum cholesterol levels without significant adverse reactions. Cerivastatin is effective and safe for patients with hypercholesterolemia who needs aggressive LDL cholesterol lowering.

Genetic Factors of Cerebral Small Vessel Disease and Their Potential Clinical Outcome

Giau, Vo Van,Bagyinszky, Eva,Youn, Young Chul,An, Seong Soo A.,Kim, Sang Yun MDPI AG 2019 INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES Vol.20 No.17

<P>Cerebral small vessel diseases (SVD) have been causally correlated with ischemic strokes, leading to cognitive decline and vascular dementia. Neuroimaging and molecular genetic tests could improve diagnostic accuracy in patients with potential SVD. Several types of monogenic, hereditary cerebral SVD have been identified: cerebral autosomal recessive arteriopathy with subcortical infarcts and leukoencephalopathy (CARASIL), cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL), cathepsin A-related arteriopathy with strokes and leukoencephalopathy (CARASAL), hereditary diffuse leukoencephalopathy with spheroids (HDLS), COL4A1/2-related disorders, and Fabry disease. These disorders can be distinguished based on their genetics, pathological and imaging findings, clinical manifestation, and diagnosis. Genetic studies of sporadic cerebral SVD have demonstrated a high degree of heritability, particularly among patients with young-onset stroke. Common genetic variants in monogenic disease may contribute to pathological progress in several cerebral SVD subtypes, revealing distinct genetic mechanisms in different subtype of SVD. Hence, genetic molecular analysis should be used as the final gold standard of diagnosis. The purpose of this review was to summarize the recent discoveries made surrounding the genetics of cerebral SVD and their clinical significance, to provide new insights into the pathogenesis of cerebral SVD, and to highlight the possible convergence of disease mechanisms in monogenic and sporadic cerebral SVD.</P>